Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16639772 | 0.85 | NAMPT (0.76) | NAMPTLMNASMN1; SMN2ALOX15HSD17B10 | |
| SCHEMBL16639782 | 0.83 | NAMPT (0.70) | NAMPTLMNASMN1; SMN2ALOX15HSD17B10 | |
| SCHEMBL16639787 | 0.79 | SMN1; SMN2 (0.55) | NAMPTLMNASMN1; SMN2ALOX15HSD17B10 | |
| SCHEMBL15246140 | 0.79 | NAMPT (1.00) | NAMPT | |
| SCHEMBL16639791 | 0.77 | ALOX15 (0.50) | NAMPTLMNASMN1; SMN2ALOX15HSD17B10 | |
| SCHEMBL16639779 | 0.77 | SMN1; SMN2 (0.65) | LMNASMN1; SMN2ALOX15HSD17B10MAPK1 | |
| SCHEMBL16639757 | 0.75 | RAB9A (0.61) | NAMPTLMNASMN1; SMN2ALOX15HSD17B10 | |
| SCHEMBL16639767 | 0.75 | ALDH1A1 (0.65) | NAMPTLMNASMN1; SMN2HSD17B10MAPK1 | |
| SCHEMBL16639797 | 0.74 | NAMPT (0.55) | NAMPTLMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL16639765 | 0.72 | NAMPT (0.62) | NAMPTLMNASMN1; SMN2ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | Valo Health, LLC | 2020-06-30 | — | — | US | disclosed |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | VALO HEALTH, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | VALO HEALTH, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | STS, SQOR, SULT1E1 | NAMPT 459/4885LMNA 3203/4885SMN1; SMN2 346/4885 |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | STS, SULT1E1, CBS | NAMPT 759/4885LMNA 3476/4885SMN1; SMN2 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.